BioCentury
ARTICLE | Clinical News

GI-5005: Interim Phase II data

May 4, 2009 7:00 AM UTC

Interim data from 117 treatment-naïve patients in an open-label Phase II trial showed that GI-5005 plus pegylated interferon and ribavirin non-significantly improved EVR to HCV RNA <25 IU/mL at week 1...